# Follicular lymphoma

Source: https://onco.cc/cancers/follicular-lymphoma/  
OnCo record `follicular-lymphoma` (Cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year.

## Summary

Follicular lymphoma (FL) is an indolent germinal-centre B-cell lymphoma defined by t(14;18) BCL2 overexpression in ~85% and frequent CREBBP, KMT2D and EZH2 mutations. Median survival now exceeds 15-20 years, so the questions are when to treat, how to avoid over-treatment, and how to manage the ~20% who progress within 24 months (POD24) and the 2-3% per year who transform to DLBCL.

Asymptomatic low-burden disease is watched or given rituximab monotherapy; symptomatic or high-burden disease receives anti-CD20 (rituximab or obinutuzumab) with bendamustine, CHOP or CVP, or with lenalidomide (R², RELEVANCE), usually followed by anti-CD20 maintenance (PRIMA). Relapsed disease has the richest menu in lymphoma: lenalidomide-rituximab (AUGMENT), CD20×CD3 bispecifics (mosunetuzumab 2022, epcoritamab 2024, odronextamab EU), CD19 CAR-T (axicabtagene 2021, tisagenlecleucel 2022, lisocabtagene 2024), zanubrutinib-obinutuzumab (ROSEWOOD, 2024) and radioimmunotherapy historically. Tazemetostat (EZH2) was withdrawn worldwide in March 2026.

Open questions: whether bispecifics or CAR-T should move to second line or even first line (EPCORE FL-1, MorningSun), PET/ctDNA-guided de-escalation, and biology-based prediction of POD24 and transformation.

## Fields

- Kind: Cancer
- Last checked: 2026-09-08
- Tags: gap-fill; haematologic
- Group: haematologic
- Burden: Follicular lymphoma is the second most common non-Hodgkin lymphoma in the West (~20% of NHL; about 3-4 per 100,000 per year), median age ~65.
- Subtypes: Classic FL (grades 1-3A); Follicular large B-cell lymphoma (formerly 3B); FL with unusual cytological features; Duodenal-type FL; Paediatric-type FL; Transformed FL
- Biomarkers: t(14;18)/BCL2; FLIPI / FLIPI2 / m7-FLIPI; PET-CT (Lugano) staging and end-of-induction response; POD24 (progression within 24 months); EZH2 mutation; ctDNA (investigational MRD)

## Sections of this record

The page is a hub with ten sections in reading order; large sections have their own page. The same plan as JSON: https://onco.cc/api/v1/cancers/follicular-lymphoma/sections.json

- Overview (on the hub): The TL;DR, the family this cancer belongs to, the organ, who gets it and what the state of the art is. https://onco.cc/cancers/follicular-lymphoma/#overview [1 subtype, 4 state-of-the-art points]
- What it is (on the hub): Anatomy, the subtypes and how they differ, how it is staged, and where advanced disease spreads. https://onco.cc/cancers/follicular-lymphoma/#what-it-is [7 subtypes]
- Finding it (on the hub): How it shows itself, how it is confirmed, what screening exists, and the biomarkers clinicians test for. https://onco.cc/cancers/follicular-lymphoma/#finding-it [6 biomarkers]
- Treating it (on the hub): The standard of care by setting, the medicines, surgery and radiotherapy named in it, and the regimens behind them. https://onco.cc/cancers/follicular-lymphoma/#treating-it [4 settings, 4 regimens, 4 decisions with options]
- Evidence (own page): Trials recruiting now, the landmark trials, the key papers and what they mean, the latest literature, and the milestones year by year. https://onco.cc/cancers/follicular-lymphoma/evidence/ [49 trials, 6 key papers, 10 milestones]
- The science (on the hub): The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models. https://onco.cc/cancers/follicular-lymphoma/#science [19 targets, 2 pathways]
- Where you are (own page): Cases by country, the UK and NHS pathway and other country lenses, and the expert centres with trials on record. https://onco.cc/cancers/follicular-lymphoma/where-you-are/ [4 centres]
- Living with it (on the hub): The decisions you may face, the aids that walk through them, the warnings on record, the first sixty days and the questions to ask. https://onco.cc/cancers/follicular-lymphoma/#living-with-it [19 questions, 6 red cards]
- What is coming (own page): Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record. https://onco.cc/cancers/follicular-lymphoma/coming/ [28 medicines, 49 trials, 4 open problems]
- Data (own page): Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked. https://onco.cc/cancers/follicular-lymphoma/data/ [177 connected records]

## Standard of care

- Limited stage (I-II): Involved-site radiotherapy 24 Gy (FoRT); rituximab alone or observation in selected cases. ([Rituximab](https://onco.cc/drugs/rituximab/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [FoRT](https://onco.cc/trials/fort/))
- Advanced, low burden, asymptomatic: Watch and wait (no survival penalty), or rituximab monotherapy to delay chemotherapy. ([Rituximab](https://onco.cc/drugs/rituximab/), [Active surveillance](https://onco.cc/technologies/active-surveillance/))
- Advanced, high burden (GELF criteria): Bendamustine-rituximab or bendamustine-obinutuzumab (GALLIUM), R-CHOP, or lenalidomide-rituximab (RELEVANCE); anti-CD20 maintenance 2 years (PRIMA). ([Rituximab](https://onco.cc/drugs/rituximab/), [Obinutuzumab](https://onco.cc/drugs/obinutuzumab/), [Bendamustine](https://onco.cc/drugs/bendamustine/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [GALLIUM](https://onco.cc/trials/gallium/), [RELEVANCE](https://onco.cc/trials/relevance/))
- Relapsed (≥2 lines): Lenalidomide-rituximab (AUGMENT); CD20×CD3 bispecific (mosunetuzumab, epcoritamab); CD19 CAR-T (axi-cel, tisa-cel, liso-cel); zanubrutinib + obinutuzumab; clinical trials. ([Mosunetuzumab](https://onco.cc/drugs/mosunetuzumab/), [Epcoritamab](https://onco.cc/drugs/epcoritamab/), [Axicabtagene ciloleucel](https://onco.cc/drugs/axicabtagene-ciloleucel/), [Tisagenlecleucel](https://onco.cc/drugs/tisagenlecleucel/), [Lisocabtagene maraleucel](https://onco.cc/drugs/lisocabtagene-maraleucel/), [Zanubrutinib](https://onco.cc/drugs/zanubrutinib/), [Odronextamab](https://onco.cc/drugs/odronextamab/))

## State of the art

- Chemotherapy-free options now exist at every line: R² first line, bispecifics and BTK-anti-CD20 combinations at relapse.
- CAR-T gives durable remissions in heavily pretreated FL (ZUMA-5 ~50% progression-free at 4 years) and is being tested against bispecifics.
- POD24 identifies the high-risk fifth; how to treat them differently up front is still unknown.
- Trials of bispecific plus lenalidomide first line (EPCORE FL-2, CELESTIMO) will decide whether chemotherapy leaves front-line FL.

## Open problems

- Transformation to DLBCL cannot be predicted or prevented.
- Sequencing bispecifics vs CAR-T.
- Whether earlier intensive therapy for POD24 patients improves survival.
- Late toxicities of decades of therapy (secondary cancers, infections, immunoglobulin loss).

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Follicular_lymphoma
- NCCN Guidelines: B-Cell Lymphomas: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480
- NCI PDQ: adult NHL: https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq
- Lymphoma Research Foundation: FL: https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/fl/

## Connected records

- collections: [Leukemia & Lymphoma Society (LLS)](https://onco.cc/collections/leukemia-lymphoma-society/), [Lymphoma Research Foundation (LRF)](https://onco.cc/collections/lymphoma-research-foundation/)
- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Marginal zone lymphoma](https://onco.cc/cancers/marginal-zone-lymphoma/), [Nodal marginal zone lymphoma](https://onco.cc/cancers/nodal-marginal-zone-lymphoma/), [Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)](https://onco.cc/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/), [Primary cutaneous follicle centre lymphoma](https://onco.cc/cancers/primary-cutaneous-follicle-centre-lymphoma/), [Waldenström macroglobulinaemia](https://onco.cc/cancers/waldenstrom/)
- technologies: [Active surveillance](https://onco.cc/technologies/active-surveillance/), [Autologous CAR-T manufacturing, batch by batch](https://onco.cc/technologies/car-t-manufacturing-process/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [PET/CT](https://onco.cc/technologies/pet-ct/), [Radio-antibody & radio-ADC](https://onco.cc/technologies/radioimmunotherapy/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [BCL-2](https://onco.cc/targets/bcl2/), [BTK (Bruton tyrosine kinase)](https://onco.cc/targets/btk/), [CD19](https://onco.cc/targets/cd19/), [CD20](https://onco.cc/targets/cd20/), [CD3](https://onco.cc/targets/cd3/), [CD3D](https://onco.cc/targets/cd3d/), [CD3G](https://onco.cc/targets/cd3g/), [CD79b](https://onco.cc/targets/cd79b/), [CSNK1E](https://onco.cc/targets/csnk1e/), [CUL4A](https://onco.cc/targets/cul4a/), [DDB1](https://onco.cc/targets/ddb1/), [EZH2](https://onco.cc/targets/ezh2/), [PI3K delta (PIK3CD)](https://onco.cc/targets/pik3cd/), [PIK3CG](https://onco.cc/targets/pik3cg/), [RBX1](https://onco.cc/targets/rbx1/)
- drugs: [Abexinostat](https://onco.cc/drugs/abexinostat/), [Axicabtagene ciloleucel](https://onco.cc/drugs/axicabtagene-ciloleucel/), [Bendamustine](https://onco.cc/drugs/bendamustine/), [Chlorambucil](https://onco.cc/drugs/chlorambucil/), [Copanlisib](https://onco.cc/drugs/copanlisib/), [CRC01](https://onco.cc/drugs/crc01/), [CTX112](https://onco.cc/drugs/ctx112/), [Epcoritamab](https://onco.cc/drugs/epcoritamab/), [Golcadomide](https://onco.cc/drugs/golcadomide/), [Ibritumomab tiuxetan](https://onco.cc/drugs/ibritumomab-tiuxetan/), [Idelalisib](https://onco.cc/drugs/idelalisib/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Linperlisib](https://onco.cc/drugs/linperlisib/), [Lisocabtagene maraleucel](https://onco.cc/drugs/lisocabtagene-maraleucel/), [MK-1045](https://onco.cc/drugs/mk-1045/), [Mosunetuzumab](https://onco.cc/drugs/mosunetuzumab/), [Obinutuzumab](https://onco.cc/drugs/obinutuzumab/), [Odronextamab](https://onco.cc/drugs/odronextamab/), [Plerixafor](https://onco.cc/drugs/plerixafor/), [Relmacabtagene autoleucel](https://onco.cc/drugs/relmacabtagene-autoleucel/), [Rituximab](https://onco.cc/drugs/rituximab/), [SCTB35](https://onco.cc/drugs/sctb35/), [Tazemetostat](https://onco.cc/drugs/tazemetostat/), [TC011](https://onco.cc/drugs/tc011/), [Tisagenlecleucel](https://onco.cc/drugs/tisagenlecleucel/), [Umbralisib](https://onco.cc/drugs/umbralisib/), [XNW5004](https://onco.cc/drugs/xnw5004/), [Zanubrutinib](https://onco.cc/drugs/zanubrutinib/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/), [Acrotech Biopharma](https://onco.cc/companies/acrotech-biopharma/), [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/), [Biogen](https://onco.cc/companies/biogen/), [Evopoint Biosciences](https://onco.cc/companies/evopoint-biosciences/), [Fondazione Italiana Linfomi](https://onco.cc/companies/fondazione-italiana-linfomi/), [Genmab](https://onco.cc/companies/genmab/), [Gilead Sciences (incl. Kite)](https://onco.cc/companies/gilead/), [Haihe Biopharma](https://onco.cc/companies/haihe-biopharma/), [Lupeng Pharmaceuticals](https://onco.cc/companies/lupeng-pharmaceuticals/), [MEI Pharma](https://onco.cc/companies/mei-pharma/), [ModeX Therapeutics](https://onco.cc/companies/modex-therapeutics/), [Mundipharma](https://onco.cc/companies/mundipharma/), [Regeneron](https://onco.cc/companies/regeneron/), [Roche / Genentech](https://onco.cc/companies/roche-genentech/), [SecuraBio](https://onco.cc/companies/securabio/), [Shanghai Yingli Pharmaceutical](https://onco.cc/companies/shanghai-yingli/), [Sinocelltech](https://onco.cc/companies/sinocelltech/), [SymBio Pharmaceuticals](https://onco.cc/companies/symbio-pharmaceuticals/), [TG Therapeutics](https://onco.cc/companies/tg-therapeutics/), [Vironexis Biotherapeutics](https://onco.cc/companies/vironexis-biotherapeutics/)
- pathways: [Complement in cancer](https://onco.cc/pathways/complement-in-cancer/), [Intrinsic apoptosis (BCL-2 family)](https://onco.cc/pathways/apoptosis-bcl2/)
- terms: [Deauville five-point scale](https://onco.cc/terms/deauville-score/), [FLIPI, FLIPI2 and POD24 (follicular lymphoma risk)](https://onco.cc/terms/flipi/), [Histologic transformation](https://onco.cc/terms/histologic-transformation/), [Lugano classification / Ann Arbor staging](https://onco.cc/terms/lugano-classification/)
- trials: [A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)](https://onco.cc/trials/nct07634471/), [A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies](https://onco.cc/trials/nct05006716/), [A Long-term Extension Study of PCI-32765 (Ibrutinib)](https://onco.cc/trials/nct01804686/), [A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma](https://onco.cc/trials/nct03934567/), [A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma](https://onco.cc/trials/nct04669171/), [A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma](https://onco.cc/trials/nct04379167/), [A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa](https://onco.cc/trials/nct04680052/), [A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)](https://onco.cc/trials/nct01827605/), [A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma](https://onco.cc/trials/nct05888493/), [A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies](https://onco.cc/trials/nct05643742/), [A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomi](https://onco.cc/trials/nct04712097/), [A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokineti](https://onco.cc/trials/nct04246086/), [A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)](https://onco.cc/trials/nct03162536/), [A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies](https://onco.cc/trials/nct07609862/), [A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients](https://onco.cc/trials/nct06549595/), [A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphom](https://onco.cc/trials/nct05100862/), [A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-](https://onco.cc/trials/nct05458297/), [A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus ](https://onco.cc/trials/nct04224493/), [A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Rela](https://onco.cc/trials/nct06911502/), [A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refr](https://onco.cc/trials/nct05451810/), [A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma](https://onco.cc/trials/nct06425302/), [A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma](https://onco.cc/trials/nct07562022/), [A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participant](https://onco.cc/trials/nct06149286/), [A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemo](https://onco.cc/trials/nct06097364/), [A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy ](https://onco.cc/trials/nct06091254/), [AUGMENT](https://onco.cc/trials/augment/), [Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma](https://onco.cc/trials/nct07545603/), [Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma](https://onco.cc/trials/nct07249905/), [Emapalumab Prevention of CAR-T Cell Associated Toxicities](https://onco.cc/trials/nct06550141/), [FoRT](https://onco.cc/trials/fort/), [GALLIUM](https://onco.cc/trials/gallium/), [Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)](https://onco.cc/trials/nct06533579/), [MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma](https://onco.cc/trials/nct04834024/), [MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)](https://onco.cc/trials/nct04110301/), [Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma](https://onco.cc/trials/nct05326243/), [RELEVANCE](https://onco.cc/trials/relevance/), [Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL](https://onco.cc/trials/nct06093841/), [Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)](https://onco.cc/trials/nct04663347/), [Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma](https://onco.cc/trials/nct03600441/), [Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma](https://onco.cc/trials/nct05371093/), [Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients](https://onco.cc/trials/nct04836507/), [Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients](https://onco.cc/trials/nct07473167/), [Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease ](https://onco.cc/trials/nct06191744/), [Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease ](https://onco.cc/trials/nct05409066/), [Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma](https://onco.cc/trials/nct02793583/), [Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL](https://onco.cc/trials/nct06526793/), [Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader](https://onco.cc/trials/nct05294731/), [Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)](https://onco.cc/trials/nct04542824/), [ZUMA-5](https://onco.cc/trials/zuma-5/)
- journals: [Clinical lymphoma, myeloma & leukemia](https://onco.cc/journals/clinical-lymphoma-myeloma-and-leukemia/), [Current hematologic malignancy reports](https://onco.cc/journals/current-hematologic-malignancy-reports/), [Hematological oncology](https://onco.cc/journals/hematological-oncology/), [Leukemia & lymphoma](https://onco.cc/journals/leukemia-and-lymphoma/)
- people: [Caron A. Jacobson](https://onco.cc/people/caron-jacobson/), [Franck Morschhauser](https://onco.cc/people/franck-morschhauser/), [Gilles Salles](https://onco.cc/people/gilles-salles/), [John P. Leonard](https://onco.cc/people/john-leonard/), [Sattva S. Neelapu](https://onco.cc/people/sattva-neelapu/), [Stephen J. Schuster](https://onco.cc/people/stephen-schuster/), [Yuqin Song](https://onco.cc/people/yuqin-song/)
- key papers: [EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T](https://onco.cc/key-papers/paper-epcore-nhl-1-epcoritamab-jco-2023/), [FoRT long-term follow-up: 4 Gy versus 24 Gy for follicular and marginal zone lymphoma](https://onco.cc/key-papers/paper-fort-long-term-follow-up-hoskin-lancet-oncol-2021/), [FoRT: 4 Gy versus 24 Gy radiotherapy for indolent lymphoma, a randomised phase 3 non-inferiority trial](https://onco.cc/key-papers/paper-fort-4gy-vs-24gy-indolent-lymphoma-hoskin-lancet-oncol-2014/), [GALLIUM: obinutuzumab for the first-line treatment of follicular lymphoma](https://onco.cc/key-papers/paper-gallium-obinutuzumab-first-line-follicular-lymphoma-marcus-nejm-2017/), [RELEVANCE: rituximab plus lenalidomide in advanced untreated follicular lymphoma](https://onco.cc/key-papers/paper-relevance-rituximab-lenalidomide-follicular-lymphoma-morschhauser-nejm-2018/), [ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma](https://onco.cc/key-papers/paper-zuma-1-axi-cel-nejm-2017/)
- institutions: [Fred & Pamela Buffett Cancer Center](https://onco.cc/institutions/nebraska-buffett/), [Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine](https://onco.cc/institutions/weill-cornell-meyer-cancer-center/), [The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute](https://onco.cc/institutions/osu-james/), [Wilmot Cancer Institute, University of Rochester](https://onco.cc/institutions/wilmot/)
- biomarkers: [CD19 expression (CD19-positive)](https://onco.cc/biomarkers/cd19-expression/), [CD20 expression (CD20-positive)](https://onco.cc/biomarkers/cd20-expression/)

---
JSON: https://onco.cc/api/v1/entities/follicular-lymphoma.json